The first reported homogenous rare earth curcumin (HCurc; ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione)) complexes with the formula ML3, where M(3+) is Eu(III), Gd(III) or Lu(III), were synthesized and characterized by mass spectrometry, infrared spectroscopy and, in the case of the lutetium complex, (1)H NMR spectroscopy. Most importantly an improved separation of the three curcuminoids, HCurc, HDMC ((1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione) and HBDMC ((1E,6E)-1,7-bis(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione) was realized using a combination of normal-phase column and phosphate-impregnated preparative-thin layer chromatographies. The toxicities of the metal curcumin complexes and ligands were investigated in MG-63 cells, an osteoblast-like cell line, for potential activity as antiosteoporotic agents.
Keywords: Antiosteoporotic agents; Curcumin; Lanthanides; Rare earths; Toxicity.
Copyright © 2013 Elsevier Inc. All rights reserved.